{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Detection of EGFR T790M alterations in plasma using the OncotypeSEQ Liquid Select assay. Progression on EGFR targeting therapy (erlotinib, gefitinib, afatinib) assessed clinically or radiologically","groups":[{"description":"Patients with non-squamous NSCLC who are progressing on erlotinib, gefitinib, or afatinib","id":"OG000","title":"Patients With Non-squamous NSCLC Who Are Progressing on Erloti"}],"paramType":"NUMBER","populationDescription":"Non-squamous NSCLC patients who progressed on erlotinib, gefitinib, or afatinib treatment and received mutation testing on both their plasma and tissue samples.","reportingStatus":"POSTED","timeFrame":"Time between patient tumor tissue biopsy and and blood collection (blood collected after the patient progressed on EGFR targeted therapy)","title":"Percentage of Participants With EGFR T790M Alterations in Plasma in Patients Progressing on EGFR Targeting Therapy (Erlotinib, Gefitinib, Afatinib).","type":"SECONDARY","unitOfMeasure":"percentage of participants"}